Vitamin D Sleep Randomized Trial: What the Evidence Says

Quick Answer

Vitamin D Sleep Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Globally, hypertension is renowned as the leading risk factor for cardiovascular disease morbidity and mortality. [Sinclair Jonathan (2026); evidence level 2]
• High blood pressure ranks first among modifiable risk factors attributable to cardiovascular disease aetiology, accounting for the largest proportion of coronary heart disease, heart failure, and stroke events. [Sinclair Jonathan (2026); evidence level 2]
• Moreover, taking such drugs during Ramadan has been reported to increase the risk of cerebral venous thrombosis, and psychological resistance remains a major global challenge. [Iimura Jun (2026); evidence level 2]
• For instance, Ahmadi reported that zinc supplementation reduced PMD symptoms, and Tartagni reported the same for vitamin D. [Iimura Jun (2026); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For vitamin D sleep randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Sinclair Jonathan (2026). Effects of peppermint ( Mentha x piperita L.) oil on cardiometabolic outcomes in patients with pre- and stage 1 hypertension: A placebo randomized controlled trial. DOI: 10.1371/journal.pone.0344538. PMCID: PMC13105356. PMID: 42024666. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13105356/
• Iimura Jun (2026). Novel dietary FemTech based on dietary reference intakes for premenstrual and menstrual disorders: a pilot open-label randomized controlled trial of dietary intervention. DOI: 10.1186/s12905-026-04382-6. PMCID: PMC13019880. PMID: 41803877. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13019880/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.